壹生资讯-关于PARP抑制剂的应用——医生观点调研

+86
获取验证码

记住我忘记密码

还没有账号？立即注册

常用国家/地区ABCDEFGHIJKLMNOPQRSTUVWXYZ

手机号已经完成验证，请完善个人资料！

壹生身份认证协议书

本项目是由壹生提供的专业性学术分享，仅面向医疗卫生专业人士。我们将收集您是否是医疗卫生专业人士的信息，仅用于资格认证，不会用于其他用途。壹生作为平台及平台数据的运营者和负责方，负责平台和本专区及用户相关信息搜集和使用的合规和保护。
本协议书仅为了向您说明个人相关信息处理目的，向您单独征求的同意，您已签署的壹生平台《壹生用户服务协议》和《壹生隐私政策》，详见链接：
壹生用户服务协议：
https://apps.medtrib.cn/html/serviceAgreement.html
壹生隐私政策：
https://apps.medtrib.cn/html/p.html
如果您是医疗卫生专业人士，且点击了“同意”，表明您作为壹生的注册用户已授权壹生平台收集您是否是医疗卫生专业人士的信息，可以使用本项服务。
如果您不是医疗卫生专业人士或不同意本说明，请勿点击“同意”，因为本项服务仅面向医疗卫生人士，以及专业性、合规性要求等因素，您将无法使用本项服务。

同意

拒绝

同意

拒绝

知情同意书

同意

不同意并跳过

工作人员正在审核中，
请您耐心等待

审核未通过

重新提交

完善信息

{{ item.question }}

确定

收集问题

{{ item.question }}

确定

您已通过HCP身份认证和信息审核

(

5

s)

关于PARP抑制剂的应用——医生观点调研

2024-03-30作者：大白资讯

欢迎来自全国各地的妇科同道参与观点调研！

{"attendFlag":0,"createTime":1711761910000,"dayEndTime":"23:59","dayStartTime":"00:00","endTime":1730304000000,"hideVotenum":true,"id":110097661,"isBindWx":0,"isOpenValidate":0,"items":[{"createTime":1711761909000,"filepathIds":"","id":2799,"imagePattern":0,"images":[],"isMultiple":1,"isNecessary":0,"maxChoicesNum":4,"minChoicesNum":1,"options":[{"createTime":1711761910000,"description":"","filepathIds":"","id":12156,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2799,"title":"1L BRCAm OC奥拉帕利单药维持治疗","userCount":12,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12157,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2799,"title":"1L HRD+ OC奥拉帕利联合贝伐珠单抗维持治疗","userCount":14,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12158,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2799,"title":"PSR奥拉帕利单药维持治疗","userCount":11,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12159,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2799,"title":"BRCAm既往新型内分泌治疗失败的mCRPC奥拉帕利单药治疗","userCount":11,"userId":2764009}],"researchId":110097661,"title":"奥拉帕利哪些适应症已经纳入中国国家医保目录？","userCount":14,"userId":2764009},{"createTime":1711761909000,"filepathIds":"","id":2800,"imagePattern":0,"images":[],"isMultiple":0,"isNecessary":0,"maxChoicesNum":1,"minChoicesNum":1,"options":[{"createTime":1711761910000,"description":"","filepathIds":"","id":12160,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2800,"title":"40%；4年","userCount":0,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12161,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2800,"title":"50%；5年","userCount":2,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12162,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2800,"title":"65.5%；6年","userCount":2,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12163,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2800,"title":"65.5%；超6年","userCount":10,"userId":2764009}],"researchId":110097661,"title":"PAOLA-1研究证实，奥拉帕利联合贝伐珠单抗的5年OS率和mOS分别为？","userCount":14,"userId":2764009},{"createTime":1711761909000,"filepathIds":"","id":2801,"imagePattern":0,"images":[],"isMultiple":0,"isNecessary":0,"maxChoicesNum":1,"minChoicesNum":1,"options":[{"createTime":1711761910000,"description":"","filepathIds":"","id":12164,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2801,"title":"20%","userCount":0,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12165,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2801,"title":"32%","userCount":0,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12166,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2801,"title":"43%","userCount":13,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12167,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2801,"title":"51%","userCount":1,"userId":2764009}],"researchId":110097661,"title":"根据PAITC研究，HRD+人群中，奥拉帕利联合贝伐珠单抗较尼拉帕利单药降低疾病进展或死亡风险？","userCount":14,"userId":2764009},{"createTime":1711761909000,"filepathIds":"","id":2802,"imagePattern":0,"images":[],"isMultiple":1,"isNecessary":0,"maxChoicesNum":4,"minChoicesNum":1,"options":[{"createTime":1711761910000,"description":"","filepathIds":"","id":12168,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2802,"title":"TSO500和MyChoice Plus","userCount":12,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12169,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2802,"title":"AmoyDx和Precision Human","userCount":14,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12170,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2802,"title":"华然迪","userCount":12,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12171,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2802,"title":"GeneseeqPrime","userCount":10,"userId":2764009}],"researchId":110097661,"title":"如下哪些HRD检测方法在国内有一致性数据或临床有效性验证结果？","userCount":14,"userId":2764009},{"createTime":1711761909000,"filepathIds":"","id":2803,"imagePattern":0,"images":[],"isMultiple":0,"isNecessary":0,"maxChoicesNum":1,"minChoicesNum":1,"options":[{"createTime":1711761910000,"description":"","filepathIds":"","id":12172,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2803,"title":"常规首推HRD","userCount":4,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12173,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2803,"title":"BRCA检测阴性后常规推荐","userCount":9,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12174,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2803,"title":"完全不推荐","userCount":0,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12175,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2803,"title":"选择部分人群推荐","userCount":1,"userId":2764009}],"researchId":110097661,"title":"随着PAOLA-1适应症纳入国家医保目录，您会如何推荐HRD检测？","userCount":14,"userId":2764009},{"createTime":1711761909000,"filepathIds":"","id":2804,"imagePattern":0,"images":[],"isMultiple":0,"isNecessary":0,"maxChoicesNum":1,"minChoicesNum":1,"options":[{"createTime":1711761910000,"description":"","filepathIds":"","id":12176,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2804,"title":"HRD+患者均推荐","userCount":7,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12177,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2804,"title":"在HRD+中仅高危患者推荐","userCount":6,"userId":2764009},{"createTime":1711761910000,"description":"","filepathIds":"","id":12178,"images":[],"isRight":0,"researchId":110097661,"researchItemId":2804,"title":"不推荐","userCount":1,"userId":2764009}],"researchId":110097661,"title":"PAOLA-1适应症已于24年1月1日执行医保，对于1L HRD+晚期OC患者，您会如何推荐？","userCount":14,"userId":2764009}],"itemsMap":{2800:{"isMultiple":0,"rightOptions":[]},2801:{"isMultiple":0,"rightOptions":[]},2802:{"isMultiple":1,"rightOptions":[]},2803:{"isMultiple":0,"rightOptions":[]},2804:{"isMultiple":0,"rightOptions":[]},2799:{"isMultiple":1,"rightOptions":[]}},"joinRange":0,"mark":2,"modifyTime":1711761909000,"researchType":0,"startTime":1711641600000,"title":"PARP抑制剂应用调研","userId":2764009,"voteCount":1}

200 评论

查看更多

互联网药品信息服务资格证书编号：(京)-非经营性-2015-0077 | 京ICP备15004031号-2｜违法和不良信息举报方式：（010）64036988 office@cmt.com.cn

京公网安备 11010202008182号

| 互联网新闻信息服务许可证编号：10120190017

Copyright © 2017-2021 中国医学论坛报社. All rights reserved.